2023

Gulliver, C., Busiau, T., Byrne, A., Findlay, J. E., Hoffmann, R. and Baillie, G. (2023) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. Molecular Oncology, (doi: 10.1002/1878-0261.13572) (PMID:38126155) (Early Online Publication)

Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, 9(9), (doi: 10.2144/fsoa-2023-0064) (PMID:37752916) (PMCID:PMC10518809)

Parsons, E. C. , Baillie, G. S. and Hoffmann, R. (2023) Revisiting the roles of cAMP signalling in the progression of prostate cancer. Biochemical Journal, 480(20), pp. 1599-1614. (doi: 10.1042/BCJ20230297)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies. British Journal of Cancer, (doi: 10.1038/s41416-023-02417-5) (PMID:37740039) (Early Online Publication)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)

2022

Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)

2021

Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)

2018

van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)

2015

Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)

2014

Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)

Articles

Gulliver, C., Busiau, T., Byrne, A., Findlay, J. E., Hoffmann, R. and Baillie, G. (2023) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. Molecular Oncology, (doi: 10.1002/1878-0261.13572) (PMID:38126155) (Early Online Publication)

Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, 9(9), (doi: 10.2144/fsoa-2023-0064) (PMID:37752916) (PMCID:PMC10518809)

Parsons, E. C. , Baillie, G. S. and Hoffmann, R. (2023) Revisiting the roles of cAMP signalling in the progression of prostate cancer. Biochemical Journal, 480(20), pp. 1599-1614. (doi: 10.1042/BCJ20230297)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies. British Journal of Cancer, (doi: 10.1038/s41416-023-02417-5) (PMID:37740039) (Early Online Publication)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)

Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)

Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)

van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)

Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)

Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)